Dosage research on KPV

Preclinical research dose ranges

In published preclinical research on KPV, administered dose ranges in rodent inflammatory-bowel-disease and colitis models have most commonly fallen in the 5 to 100 microgram per dose range delivered orally, intraperitoneally, or intracolonically depending on the protocol. The Dalmasso and colleagues line of work in murine colitis used doses in this range across multi-day dosing protocols in DSS-induced and TNBS-induced colitis designs.

In-vitro inflammatory-cytokine studies on cultured cells (intestinal epithelial cells, macrophages, T cells) have most commonly used KPV at micromolar concentrations in the culture medium. Effects on NF-kappa-B signalling, cytokine release, and inflammatory marker panels have been reported across the 1 to 100 micromolar range. The acute in-vitro IC50 characterisation for cytokine-suppression endpoints has used sub-micromolar to micromolar concentrations.

The dermatitis and skin-inflammation literature has used topical KPV concentrations in the 0.01 to 0.1 percent range applied to the skin surface in murine models across daily-dosing protocols. The mast-cell-degranulation and histamine-release in-vitro literature has used micromolar concentrations in the cell-culture medium for acute-effect characterisation.

Dose-response considerations from the published literature

The published KPV literature has reported dose-response characteristics in colitis-endpoint studies across the microgram-per-dose range in murine DSS and TNBS colitis models. Effects on inflammatory cytokine release, histological inflammation scores, and disease-activity indices scaled with administered dose across the tested range. Topical-application dose-response work in dermatitis models has reported maximum effects at the 0.05 to 0.1 percent concentration range.

No Phase 1 or Phase 2 dose-ranging trial of KPV has appeared in the indexed clinical-trial literature at the time of writing. The compound remains in preclinical and translational research, and the research community continues to rely on the rodent in-vivo and in-vitro literature for dose-design inference.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised KPV vial reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 5 mg per mL. From this stock, a research aliquot of 0.1 mL contains 500 micrograms; an aliquot of 0.02 mL contains 100 micrograms. Researchers working with the microgram-per-dose ranges reported in published rodent colitis protocols further dilute the stock to a working concentration appropriate to the model and the dosing route. For in-vitro studies at micromolar working concentrations, the stock is further diluted by several orders of magnitude into the cell-culture medium. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice.

Research-protocol design considerations

Protocol-design choices in the published KPV literature reflect several recurring considerations. Dose selection in colitis studies anchors at the 5 to 100 microgram per dose range. In-vitro dose selection anchors at the 1 to 100 micromolar range in cell-culture medium. Topical-application dose selection in dermatitis studies anchors at the 0.01 to 0.1 percent concentration range.

Route of administration in the published rodent work matches the endpoint: oral and intracolonic for colitis endpoints, topical for dermatitis endpoints, intraperitoneal and subcutaneous for systemic endpoints. The route selection is one of the primary protocol-design decisions for KPV research and reflects the target-tissue accessibility considerations relevant to the inflammatory endpoint being measured.

The alpha-MSH C-terminal fragment origin is a protocol-design consideration for investigators interested in melanocortin-receptor-related effects. KPV reproduces some of the anti-inflammatory profile of intact alpha-MSH without engaging the melanocortin receptors directly in the same way; protocol designs interested in distinguishing melanocortin-receptor-mediated from melanocortin-receptor-independent effects use this distinction in comparator-arm experimental design.

References

1. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. [PMID 18054561]
2. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. [PMID 18537211]
3. Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocrine Reviews, 2008. [PMID 18653702]
4. Catania A et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews, 2004. [PMID 14722319]
5. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal, 1989. [PMID 2606764]
6. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 2007. [PMID 17934089]